To prevent surgery-related shortcomings, several non-surgical (e.g. mechanical) and enzymatic debriding means are still used but all are inefficiently slow and may involve eschar and wound-handling complications.
Existing enzymatic debriding agents derive from animal, plant or bacterial origin. These include streptokinase, collagenase, papain/urea, and other combinations. Many of them are not in high demand for burn debridement due to relatively poor efficacy.
NexoBrid™ is the first of a new generation of non-surgical effective eschar-specific removal agents. NexoBrid™ contains a mixture of enzymes enriched in bromelain, which dissolve burn wound eschar.
NexoBrid™ has been investigated in over 550 patients in Phase II and Phase III clinical studies by more than 100 leading burn specialists from 15 countries and 4 continents.